Overview

Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL

Status:
Unknown status

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

This study is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL).

Phase:

Phase 3

Details

Lead Sponsor:

Acerta Pharma BV

Treatments:

Acalabrutinib
Chlorambucil
Obinutuzumab